In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis acquires neuromuscular gene therapy firm AveXis for $8.7bn

Executive Summary

Novartis AG agreed to acquire public gene therapy company AveXis Inc. (focused on rare neuromuscular diseases) for $8.7bn. The deal has an enterprise value of $8.4bn.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register